Holiday Notification: Cayman Chemical will be closed Monday, May 28, 2012, in observance of the Memorial Day holiday.
More…
Please feel free to continue placing orders via our website or via fax at 734-971-3640. You may send an email to customer service at custserv@caymanchem.com , or to technical support at techserv@caymanchem.com which we will respond to the next business day. Cayman will resume regular business hours and shipping schedules on Tuesday, May 29, 2012. Thank you for your patience and understanding.
Overactivity of the epidermal growth factor (EGF) receptor-associated tyrosine kinase has been associated with a number of cancers and thus tyrosine kinase inhibitors could be potential therapeutic agents to prevent malignant growth.1 Erbstatin is a potent, small-molecule inhibitor of EGF receptor-associated tyrosine kinase. However, it is highly unstable, inactivating completely within 30 minutes in calf serum.2 Erbstatin analog is a stable, potent inhibitor of EGFR kinase activity. It is four-times more stable than erbstatin in calf serum and inhibits EGFR tyrosine kinase in vitro similar to erbstatin with an IC50 value of 0.14 µg/ml.2 Erbstatin analog inhibits EGF-stimulated growth in EGFR-overexpressing NIH3T3 cells with an IC50 value of 0.5 µg/ml and efficiently delays the onset of EGF-induced DNA synthesis.3
1
Sausville, E.A., Elsayed, Y., Monga, M., et al. Signal transduction-directed cancer treatments. Annu Rev Pharmacol Toxicol43199-231(2003).
2
Umezawa, K., Hori, T., Tajima, H., et al. Inhibition of epidermal growth factor-induced DNA synthesis by tyrosine kinase inhibitors. FEBS Lett260(2)198-200(1990).
3
Umezawa, K., Sugata, D., Yamashita, K., et al. Inhibition of epidermal growth factor receptor functions by tyrosine kinase inhibitors in NIH3T3 cells. FEBS Lett314(3)289-292(1992).
Room temperature
in continental US; may vary elsewhere
SMILES
Copy SMILES to clipboard
COC(=O)\C=C/c1cc(O)ccc1O
Background Reading
Umezawa, K., Hori, T., Tajima, H., et al. Inhibition of epidermal growth factor-induced DNA synthesis by tyrosine kinase inhibitors. FEBS Lett260(2)198-200(1990).
Umezawa, K., Sugata, D., Yamashita, K., et al. Inhibition of epidermal growth factor receptor functions by tyrosine kinase inhibitors in NIH3T3 cells. FEBS Lett314(3)289-292(1992).
Sausville, E.A., Elsayed, Y., Monga, M., et al. Signal transduction-directed cancer treatments. Annu Rev Pharmacol Toxicol43199-231(2003).
Erbstatin Analog is available in the following screening
library: